Scinai

18/09/2025

🍎✨ 𝐒𝐡𝐚𝐧𝐚 𝐓𝐨𝐯𝐚 – 𝐇𝐚𝐩𝐩𝐲 𝐉𝐞𝐰𝐢𝐬𝐡 𝐍𝐞𝐰 𝐘𝐞𝐚𝐫 ✨🍯
As we welcome 5786, we wish all our customers, partners, colleagues, and followers a year filled with peace, health, growth, prosperity, and meaningful progress. May our collaborations continue to flourish and reach new heights together.
This holiday, our hearts are with the 48 hostages still held captive by Hamas, and we pray for their immediate return, for healing, an end to the war, and the safe return of all our soldiers.
Wishing you a happy and successful New Year, from all of us at Scinai.

16/09/2025

Wrapping up a fantastic (last) week for Scinai!

Our CEO, Amir Reichman, had an incredible time connecting with investors, partners, and fellow innovators at both the H.C. Wainwright Annual Global Investment Conference in New York City and the 16th Annual World Bispecific Summit in Boston.

From insightful discussions to meaningful new connections, these events were a great opportunity to share Scinai’s progress and explore collaborations that advance next-generation immunotherapies.

A big thank you to everyone who took the time to meet with us, your interest and engagement inspire us as we continue to grow.

09/09/2025

CYMI: Scinai Reported Positive Results for the First Half of the Year in their Q2 Report!

In this 90 second review, see how we’ve driven growth and efficiency in the first half of 2025. Some of those core highlights include:

✅ Raised more than $4M through our SEPA agreement
✅ Reduced operating expenses by 50% while advancing R&D activities
✅ Boosted CDMO revenues by 2.5x vs. the same period last year

We’re proud of the progress made in the first half of 2025 and excited for the road ahead.

Watch the full recap video below and sign up on our website for the latest updates!

Send a message to learn more

03/09/2025

📢 Save the Date!

Scinai will be attending two major industry events this September:

📍 H.C. Wainwright Annual Global Investment Conference
🗓️ September 8–10, 2025
📌 Lotte New York Palace Hotel, New York City

📍 16th Annual World Bispecific Summit
🗓️ September 9–11, 2025
📌 Boston, MA

We look forward to engaging with investors, partners, and industry leaders to share Scinai’s vision and progress in advancing next-generation immunotherapies.

Stay tuned for more updates, and we hope to see you there!

02/09/2025

Scinai Immunotherapeutics Ltd. Reports 1H 2025 Results: Highlighting CDMO Revenue Growth and a Strengthened Balance Sheet

Scinai kicked off 2025 with strong financial and operational momentum, particularly within our CDMO business unit, Scinai BioServices.

1H 2025 Highlights:

- Revenues totaled $773,000 compared to $284,000 for the six months ended June 30, 2024. The increase reflects the continued growth of the Company's CDMO business, which generated contract revenues.
- Cash position increased as we successfully raised an additional $4.2 million through our Standby Equity Purchase Agreement with Yorkville Advisors
- Scinai filed patents for four additional NanoAbs from its collaboration with the Max Planck Society and University Medical Center Göttingen and is exercising its exclusive option to license them.

These results reflect Scinai’s focused ex*****on on our dual strategy of advancing a pipeline of novel biologics for I&I indications as well as scaling CDMO operations to serve the growing needs of biopharma innovators.

Read the full press release: https://www.prnewswire.com/news-releases/scinai-reports-six-month-2025-financial-results-highlighting-continued-cdmo-revenue-growth-and-strengthened-balance-sheet-302543710.html

14/08/2025

This August for Psoriasis Awareness Month, we’re highlighting Scinai’s work to advance NanoAbs, nanosized antibodies designed for high stability and precise targeting, starting with an Anti‑IL‑17 program in preclinical development for psoriasis.

With in‑house GMP biologics CDMO capabilities and strong collaborations, we’re building an ex*****on engine to move novel inflammation therapeutics from bench to bedside.

Follow Scinai for progress updates and partnering opportunities. Visit us at our website: https://www.scinai.com/

07/08/2025

What Are NanoAbs and Why Do They Matter?

NanoAbs are single-domain antibodies derived from alpacas that consist solely of a heavy chain, in contrast to traditional monoclonal antibodies (mAbs), which contain both heavy and light chains. This streamlined structure gives NanoAbs a range of unique and advantageous properties:

✅ 10X Smaller Than Conventional mAbs – Their compact size enables lower production costs and may reduce off-target binding and side effects.
✅ High Stability – NanoAbs retain biological activity in harsh environments, which supports a simplified supply chain and longer shelf life.
✅ Flexible Administration Routes – Effective for both localized (e.g., intradermal or inhalation) and systemic treatments, enhancing their therapeutic versatility.
✅ Versatile Protein Engineering – NanoAbs function like Lego blocks, allowing scientists to design innovative molecular architectures such as monomers for local delivery or multi-specific constructs for systemic use. In contrast, traditional mAbs are more rigid—like Playmobil figures—offering far less design flexibility.

Why This Matters for Investors?

✅ Massive Market Opportunity – The psoriasis biologics market alone is projected to exceed $35 billion by 2030, with broader potential in autoimmune and inflammatory diseases.
✅ Disruptive Technology Platform – Scinai’s NanoAb platform delivers clear advantages over conventional antibody therapies, thanks to its smaller size, higher stability, modularity, and expanded administration options.
✅ Focused and Scalable Pipeline – Our lead IL-17 A/F NanoAb program targets psoriasis and other inflammatory indications, while additional candidates are advancing toward clinical readiness.

Scinai is building a next-generation NanoAb platform, combining scientific innovation with strategic focus, to unlock exceptional value in a rapidly growing global market.

Learn more about Scinai Immunotherapeutics
🔗 https://www.scinai.com/

29/07/2025

BREAKING: New Study Highlights PC111 as a Potential Game-Changer in Autoimmune Skin Disorders

We’re excited to share that Scinai Immunotherapeutics’ Partner Pincell has published a peer-reviewed study confirming the disease modifying potential of our lead asset, PC111, in Pemphigus and SJS/TEN - two serious, rare autoimmune skin diseases. From lab bench to validated humanized models, the data speak for themselves.

This is another major step forward in our mission to bring non-immunosuppressive, targeted therapies to patients in need
Read more about how we’re pushing boundaries in autoimmune dermatology.

30/06/2025

🏆 A proud milestone for Scinai Immunotherapeutics Ltd. and our partners at PinCell srl 🚀

Heartfelt congratulations to Dr. Roberta Lotti of PinCell srl for receiving the “Oscar of Italian Dermatology” from SIDeMaST for her pioneering work on PC111, a novel anti-Fas Ligand antibody 👏👏👏

Her award-winning research confirms PC111’s non-immunosuppressive, disease-modifying potential in Pemphigus Vulgaris, reinforcing Scinai’s strategic option to acquire Pincell and advance this transformative therapy.

Amir Reichman , CEO of Scinai Immunotherapeutics Ltd. stated:

" 𝑇ℎ𝑖𝑠 𝑟𝑒𝑐𝑜𝑔𝑛𝑖𝑡𝑖𝑜𝑛 𝑟𝑒𝑖𝑛𝑓𝑜𝑟𝑐𝑒𝑠 𝑡ℎ𝑒 𝑠𝑡𝑟𝑎𝑡𝑒𝑔𝑖𝑐 𝑚𝑒𝑟𝑖𝑡 𝑜𝑓 𝑆𝑐𝑖𝑛𝑎𝑖'𝑠 𝑠𝑒𝑐𝑢𝑟𝑖𝑛𝑔 𝑎𝑛 𝑜𝑝𝑡𝑖𝑜𝑛 𝑡𝑜 𝑎𝑐𝑞𝑢𝑖𝑟𝑒 𝑃𝑖𝑛𝑐𝑒𝑙𝑙'𝑠 𝑎𝑢𝑡𝑜𝑖𝑚𝑚𝑢𝑛𝑒 𝑑𝑒𝑟𝑚𝑎𝑡𝑜𝑙𝑜𝑔𝑦 𝑝𝑖𝑝𝑒𝑙𝑖𝑛𝑒 𝑎𝑛𝑑 𝑣𝑎𝑙𝑖𝑑𝑎𝑡𝑒𝑠 𝑜𝑢𝑟 𝑐𝑜𝑛𝑣𝑖𝑐𝑡𝑖𝑜𝑛 𝑡ℎ𝑎𝑡 𝑃𝐶111 ℎ𝑎𝑠 𝑡ℎ𝑒 𝑝𝑜𝑡𝑒𝑛𝑡𝑖𝑎𝑙 𝑡𝑜 𝑏𝑒𝑐𝑜𝑚𝑒 𝑎 𝑡𝑟𝑎𝑛𝑠𝑓𝑜𝑟𝑚𝑎𝑡𝑖𝑣𝑒, 𝑑𝑖𝑠𝑒𝑎𝑠𝑒-𝑚𝑜𝑑𝑖𝑓𝑦𝑖𝑛𝑔 𝑡ℎ𝑒𝑟𝑎𝑝𝑦. 𝑊𝑒 𝑎𝑟𝑒 𝑐𝑜𝑛𝑓𝑖𝑑𝑒𝑛𝑡 𝑡ℎ𝑖𝑠 𝑝𝑟𝑜𝑔𝑟𝑎𝑚 𝑤𝑖𝑙𝑙 𝑑𝑒𝑙𝑖𝑣𝑒𝑟 𝑠𝑖𝑔𝑛𝑖𝑓𝑖𝑐𝑎𝑛𝑡 𝑐𝑙𝑖𝑛𝑖𝑐𝑎𝑙 𝑣𝑎𝑙𝑢𝑒 𝑡𝑜 𝑝𝑎𝑡𝑖𝑒𝑛𝑡𝑠 𝑎𝑛𝑑 𝑠𝑡𝑟𝑎𝑡𝑒𝑔𝑖𝑐 𝑣𝑎𝑙𝑢𝑒 𝑡𝑜 𝑜𝑢𝑟 𝑠ℎ𝑎𝑟𝑒ℎ𝑜𝑙𝑑𝑒𝑟𝑠".

Congratulations Dr.Lotti, we're proud to support science that can redefine treatment paradigms and improve patient outcomes.

Read the press release: https://lnkd.in/e3YhTydG

09/06/2025

🎥 Video Out Now: Why Q1 2025 Marked a Breakthrough for Scinai 📈

ICYMI: We’re excited to share this quick video capturing a standout Q1 for Scinai and our team’s momentum:

🔹 CDMO revenue surged – $586K in Q1, already approaching our full‑year 2024
🔹 Streamlined expenses – R&D costs DECLINED ~17% YoY to $1.296M
🔹 Net loss narrowed – Slashed from $2.159M to $1.557M year-over-year
🔹 Financial discipline – Net financial income swung to +$11K vs. –$231K last year thanks to strategic EIB loan conversion

Behind the numbers: sharper cost management, revenue generation from CDMO contracts, and improved financing—proof of our ex*****on-driven approach as we balance biotech innovation with scalable service operations.

📌 Watch the full video to hear from our CEO on how we achieved these results—and what's next as we scale both our therapeutic pipeline and CDMO capabilities.

28/05/2025

🎥 Two De-risked Pipeline Assets. One Scalable Platform.

In this 60-second video, Scinai CEO Amir Reichman shares how Scinai Immunotherapeutics is advancing:

🔹 A differentiated nanobody platform for autoimmune diseases, which offers several advantages in clinical development AND…
🔹 A novel anti-Fas/FasL antibody (PC111) via our partnership with Pincell srl

With strong scientific foundations and a focused development path, Scinai is building a de-risked, capital-efficient pipeline targeting high-need indications.

📩 To learn more visit our website and sign up for news alerts:
https://www.scinai.com/investorsrelations

16/05/2025

Scinai Immunotherapeutics Ltd. 𝐈𝐬 𝐒𝐞𝐭 𝐭𝐨 𝐑𝐞𝐬𝐡𝐚𝐩𝐞 𝐭𝐡𝐞 𝐅𝐮𝐭𝐮𝐫𝐞 𝐨𝐟 𝐈𝐦𝐦𝐮𝐧𝐨𝐭𝐡𝐞𝐫𝐚𝐩𝐲
𝐹𝑟𝑜𝑚 𝑖𝑛𝑛𝑜𝑣𝑎𝑡𝑖𝑣𝑒 𝑛𝑎𝑛𝑜𝑏𝑜𝑑𝑦 𝑝𝑙𝑎𝑡𝑓𝑜𝑟𝑚𝑠 𝑡𝑜 𝑓𝑖𝑟𝑠𝑡-𝑖𝑛-𝑐𝑙𝑎𝑠𝑠 𝑚𝑜𝑛𝑜𝑐𝑙𝑜𝑛𝑎𝑙 𝑎𝑛𝑡𝑖𝑏𝑜𝑑𝑖𝑒𝑠, 𝑆𝑐𝑖𝑛𝑎𝑖 𝐼𝑚𝑚𝑢𝑛𝑜𝑡ℎ𝑒𝑟𝑎𝑝𝑒𝑢𝑡𝑖𝑐𝑠 𝑖𝑠 𝑜𝑛 𝑎 𝑓𝑎𝑠𝑡 𝑡𝑟𝑎𝑐𝑘 𝑡𝑜 𝑑𝑒𝑙𝑖𝑣𝑒𝑟 𝑐𝑢𝑡𝑡𝑖𝑛𝑔-𝑒𝑑𝑔𝑒 𝑡ℎ𝑒𝑟𝑎𝑝𝑖𝑒𝑠 𝑓𝑜𝑟 𝑖𝑚𝑚𝑢𝑛𝑜𝑙𝑜𝑔𝑖𝑐𝑎𝑙 𝑎𝑛𝑑 𝑎𝑢𝑡𝑜𝑖𝑚𝑚𝑢𝑛𝑒 𝑑𝑖𝑠𝑒𝑎𝑠𝑒𝑠.

🎥 Watch the video below to discover our vision, pipeline, and path forward—direct from our CEO, Amir Reichman.
🔬 Learn how we’re:
✅ Developing de-risked antibody-based therapies for high-need indications
✅ Leveraging novel delivery routes and bispecific nanobodies for superior efficacy
✅ Building a dual-platform pipeline addressing both broad and orphan diseases
✅ Advancing candidates through preclinical milestones toward Phase 2 readiness
✅ Generating revenue via our boutique CDMO facility in Jerusalem
📍 Heading to Biomed Israel 2025 or BIO International in Boston?
Let’s meet! Explore potential synergies and see how Scinai is built for partnership and progress.
📅 DM us to book a meeting or learn more: ir@scinai.com